Literature DB >> 35639043

Frailty, vaccination, and hospitalization following COVID-19 positivity in older veterans.

Benjamin Seligman1,2, Kevin Ikuta3,4, Greg Orshansky5,6, Matthew Bidwell Goetz3,4.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35639043      PMCID: PMC9349364          DOI: 10.1111/jgs.17919

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   7.538


× No keyword cloud information.

INTRODUCTION

Since the start of the COVID‐19 pandemic there have been multiple efforts to predict individual‐level risk for adverse outcomes following infection. Frailty, which attempts to capture physiologic vulnerability, is a risk factor for poor outcomes following both infection and hospitalization with COVID‐19.2, 3 Frailty has also been identified as a confounder when assessing vaccine effectiveness. However, if frailty is associated with altered vaccine effectiveness against hospitalization among individuals with COVID‐19 is not yet known. We provide a preliminary assessment of frailty and protection against hospitalization among COVID‐19 positive individuals in a large urban healthcare system.

METHODS

We assembled a cohort from administrative data of all veterans aged 50 or older who had a positive COVID‐19 PCR or antigen test at the VA Greater Los Angeles Health Care System from December 1, 2021 to January 31, 2022, covering the Omicron variant wave. Individuals were classified as fully vaccinated if they had completed a COVID‐19 vaccine series and had received or were not yet eligible for a booster; partially vaccinated if they had an incomplete vaccine series or were eligible for but had not received a booster; and unvaccinated if they had not received any COVID‐19 vaccination. Frailty was assessed using the VA frailty index. Individuals were classified as non‐frail, frail, or severely frail (FI < 0.2, 0.2–0.4, and >0.4, respectively) using data from the 36‐month period leading up to the date of testing positive for COVID‐19. The outcome was hospital admission within 30 days of the positive test result. Analysis was by logistic regression on vaccination status, frailty, age, and gender conducted in R version 4.0.5. This study was approved by the Institutional Review board of the VA Greater Los Angeles Health Care System.

RESULTS

There were 1091 individuals with a positive COVID‐19 test result with 155 admitted. 1026 (94%) were male, median (IQR) age was 67 (60–76). 519 (48%) were fully vaccinated, 271 (25%) partially vaccinated, and 301 (28%) unvaccinated. 662 (61%) were non‐frail, 335 (31%) frail, and 94 (9%) severely frail. Figure 1 shows vaccine effectiveness by frailty. For each vaccination status, those with greater degrees of frailty were more likely to be admitted. However, crude relative risk (95% CI) of admission for fully vaccinated versus unvaccinated are similar: 0.28 (0.15–0.54) for non‐frail, 0.42 (0.26–0.67) for frail, and 0.33 (0.18–0.57) for severely frail. Absolute risk differences (95% CI) for fully vaccinated versus unvaccinated increase with greater frailty: 11% (5–17) for non‐frail, 19% (8–30) for frail, and 45% (22–68) for severely frail.
FIGURE 1

Proportions of veterans hospitalized within 30 days following positive COVID‐19 test by frailty and vaccination status

Proportions of veterans hospitalized within 30 days following positive COVID‐19 test by frailty and vaccination status Table 1 shows logistic regression results for 30‐day admission following positive test. The odds of hospitalization are greater for partially‐ and un‐vaccinated individuals relative to fully‐vaccinated individuals, and greater for frail and severely‐frail individuals relative to non‐frail individuals.
TABLE 1

Results of logistic regression of 30‐day hospital admission following positive COVID‐19 test on age, vaccination status, and frailty status

VariableOdds ratio (95% CI) p value
Age (years)1.03 (1.01–1.05)<0.001
Male gender1.35 (0.59–3.71)0.513
Vaccination status
Fully vaccinated1Reference
Partially vaccinated1.85 (1.13–3.03)0.014
Unvaccinated4.13 (2.72–6.36)<0.001
Frailty status
Non‐frail (FI < 0.2)1Reference
Frail (FI 0.2–0.4)2.41 (1.61–3.62)<0.001
Severely frail (FI > 0.4)5.18 (2.96–9.03)<0.001

Abbreviation: FI, Frailty index.

Results of logistic regression of 30‐day hospital admission following positive COVID‐19 test on age, vaccination status, and frailty status Abbreviation: FI, Frailty index.

DISCUSSION

We provide early evidence that vaccination against COVID‐19 protects infected individuals against hospitalization, regardless of frailty status. Crude relative effectiveness of full vaccination was similar across the levels of frailty we considered, and crude absolute risk reduction was greatest among severely frail individuals. Adjusted analyses confirmed that vaccination against COVID‐19 protects against hospitalization among infected individuals. These demonstrate that up‐to‐date vaccination against COVID‐19 is beneficial regardless of frailty. Partial vaccination offered less protection. These results also confirm that, adjusting for vaccination status and age, frail individuals are more likely to be admitted after infection. Our study is limited by representing a single health system. Sample size restricted assessment of interaction between frailty and vaccination. The outcome includes COVID‐related and ‐unrelated admissions. Finally, due to power we aggregate individuals with incomplete primary vaccine series and those eligible for—but had not received—a booster; these groups may have different outcomes. In conclusion, this provides evidence that COVID‐19 vaccination protects against hospitalization after infection even among frail individuals. Regardless of vaccination status, frail individuals are at higher risk for hospitalization following infection. As preventive measures such as mask requirements are discontinued, clinicians should realize that frail patients remain at higher risk. Frailty may help with prioritizing antiviral therapy when resources are limited and may be an indication for future COVID‐19 boosters. Further work should consider vaccine effectiveness against additional outcomes across levels of frailty to inform how well vaccination protects those most vulnerable.

AUTHOR CONTRIBUTIONS

Benjamin Seligman, Kevin Ikuta, and Matthew Bidwell Goetz conceptualized and designed the study. Greg Orshansky collected and curated study data. Analysis was performed by Benjamin Seligman and Kevin Ikuta. The initial draft was prepared by Benjamin Seligman. All authors participated in finalizing the manuscript for submission.

CONFLICT OF INTEREST

The authors have no conflicts of interest to report.

SPONSOR'S ROLE

This study was not sponsored.
  6 in total

1.  Controlling confounding by frailty when estimating influenza vaccine effectiveness using predictors of dependency in activities of daily living.

Authors:  Henry T Zhang; Leah J McGrath; Richard Wyss; Alan R Ellis; Til Stürmer
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-08-24       Impact factor: 2.890

2.  The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study.

Authors:  Jonathan Hewitt; Ben Carter; Arturo Vilches-Moraga; Terence J Quinn; Philip Braude; Alessia Verduri; Lyndsay Pearce; Michael Stechman; Roxanna Short; Angeline Price; Jemima T Collins; Eilidh Bruce; Alice Einarsson; Frances Rickard; Emma Mitchell; Mark Holloway; James Hesford; Fenella Barlow-Pay; Enrico Clini; Phyo K Myint; Susan J Moug; Kathryn McCarthy
Journal:  Lancet Public Health       Date:  2020-06-30

3.  COVID-19 and associations with frailty and multimorbidity: a prospective analysis of UK Biobank participants.

Authors:  S J Woolford; S D'Angelo; C Cooper; N C Harvey; E M Curtis; C M Parsons; K A Ward; E M Dennison; H P Patel
Journal:  Aging Clin Exp Res       Date:  2020-07-23       Impact factor: 3.636

4.  Efficacy and safety of COVID-19 vaccines in older people.

Authors:  Roy L Soiza; Chiara Scicluna; Emma C Thomson
Journal:  Age Ageing       Date:  2021-02-26       Impact factor: 10.668

5.  Updating and Validating the U.S. Veterans Affairs Frailty Index: Transitioning From ICD-9 to ICD-10.

Authors:  David Cheng; Clark DuMontier; Cenk Yildirim; Brian Charest; Chelsea E Hawley; Min Zhuo; Julie M Paik; Enzo Yaksic; J Michael Gaziano; Nhan Do; Mary Brophy; Kelly Cho; Dae H Kim; Jane A Driver; Nathanael R Fillmore; Ariela R Orkaby
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2021-06-14       Impact factor: 6.053

6.  Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal

Authors:  Laure Wynants; Ben Van Calster; Gary S Collins; Richard D Riley; Georg Heinze; Ewoud Schuit; Marc M J Bonten; Darren L Dahly; Johanna A A Damen; Thomas P A Debray; Valentijn M T de Jong; Maarten De Vos; Paul Dhiman; Maria C Haller; Michael O Harhay; Liesbet Henckaerts; Pauline Heus; Michael Kammer; Nina Kreuzberger; Anna Lohmann; Kim Luijken; Jie Ma; Glen P Martin; David J McLernon; Constanza L Andaur Navarro; Johannes B Reitsma; Jamie C Sergeant; Chunhu Shi; Nicole Skoetz; Luc J M Smits; Kym I E Snell; Matthew Sperrin; René Spijker; Ewout W Steyerberg; Toshihiko Takada; Ioanna Tzoulaki; Sander M J van Kuijk; Bas van Bussel; Iwan C C van der Horst; Florien S van Royen; Jan Y Verbakel; Christine Wallisch; Jack Wilkinson; Robert Wolff; Lotty Hooft; Karel G M Moons; Maarten van Smeden
Journal:  BMJ       Date:  2020-04-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.